Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue: 2010-2025

Historic Current Deferred Revenue for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Sep 2025 value amounting to $1.0 million.

  • Ironwood Pharmaceuticals' Current Deferred Revenue was N/A to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2024, which is 22.44% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Current Deferred Revenue is $1.0 million, which was up 7.16% from $978,000 recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Current Deferred Revenue peaked at $2.6 million during Q4 2023, and registered a low of $978,000 during Q2 2025.
  • Its 3-year average for Current Deferred Revenue is $1.7 million, with a median of $1.8 million in 2025.
  • Data for Ironwood Pharmaceuticals' Current Deferred Revenue shows a maximum YoY declined of 22.44% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Ironwood Pharmaceuticals' Current Deferred Revenue stood at $2.6 million in 2023, then declined by 22.44% to $2.0 million in 2024, then reached $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $978,000 for Q2 2025, and $1.8 million during Q1 2025.